Hemostasis/Thrombosis

Questions discussed in this category

What genetic testing would you consider for recurrent arterial events (cryptogenic strokes, MI) in patients with limited risk factors?

Family history is notable for CVA and early onset MI in nonsmokers, but no personal or family history of VTE. APLS testing is negative. Previously fou...

1 Answer available

Would you evaluate for thrombophilia in patients with incidental splenic infarcts in the setting of known cirrhosis, portal hypertension, and splenomegaly?

How would you approach anticoagulation in this situation? Does the presence of thrombocytopenia or hemorrhagic splenic infarcts change your manag...

1 Answer available

Would you anticoagulate an SMV thrombosis caused by malignant obstruction in the setting of metastatic colorectal cancer?

For what duration and is there a preferred anticoagulation agent?

1 Answer available

How would you manage symptomatic, bilateral subsegmental PE developed after long air travel?

The patient takes frequent flights, with no prior history of VTE, and has already been taking measures for prevention including frequent ambulation, h...

2 Answers available

Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?

Labs with normal PT, but prolonged PTT (47 sec, ULN 40 sec) that does not correct on immediate mix. Lupus anticoagulant negative (DRVVT and hexagonal ...

1 Answer available

Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?

2 Answers available

How long would you anticoagulate for PE developed after air travel in a woman on an estrogen-containing vaginal ring for contraception?

Would you anticoagulate for a fixed or indefinite duration? Would you recommend changing her contraception method?

1 Answer available

How would you manage superficial thrombophlebitis of the great saphenous vein involving the knee and calf?

Would you label this as intermediate or high risk and treat with prophylactic or full dose AC? What duration would you treat for?

1 Answer available

What is your approach to symptomatic superficial thrombosis of the pelvic veins occurring in the immediate postpartum period?

No prior hx of DVT/SVT. Negative LE doppler. Would you consider anticoagulating and at what dose, or favor close observation?

1 Answer available

Would you consider caplacizumab in a pregnant patient with iTTP?

Caplacizumab is not FDA approved in pregnant patients, but has been used safely in isolated case reports.

1 Answer available

What would you recommend for long term management of extensive dural venous sinus thrombosis (CVST) in young females when the only provoking risk factor is combined OCP?

Thrombophilia testing, including JAK2 is negative. When would you stop anticoagulation?

3 Answers available

Is there any benefit to using desmopressin over vWF replacement therapy for vWD?

If not, has your practice changed to use vWF replacement therapy more routinely for perioperative or acute bleeding management? Do you still perform D...

1 Answer available

In extremely obese patients with spontaneous DVT/PE who have been anticoagulated for > 6 months, do you feel comfortable reducing the DOAC to prophylactic dose or do you prefer continuing full dose indefinite anticoagulation?

BMI>40

3 Answers available

How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?

Are there specific guidelines for managing this patient population?

1 Answer available

How do you start and manage therapeutic SC heparin for acute thrombosis in pregnancy as the patient approaches delivery?

Assume patient requires anticoagulation in the setting of acute thrombosis, with no need for IVC filter, but is approaching the end of her third trime...

1 Answer available

How would you manage a patient with family history of protein s deficiency, now with provoked VTE and low protein S?

1 Answer available

How would you manage a patient with morbid obesity who presents with new symptomatic pulmonary embolism a few days after he was started on DOAC for DVT?

What is your preferred anticoagulation in patients with BMI >50?

5 Answers available

How is your experience with point-of-care INR systems for home monitoring of vitamin K antagonists?

Are the INRs reliable? In what scenarios would you not recommend POC INR use for warfarin monitoring? Are these typically covered by insurance? Are t...

1 Answer available

How to approach reversal of TNK in hemorrhagic conversion of ischemic stroke?

Considering the short half-life, at what point would it be deemed too late to administer any reversal agent, and to consider withholding it?

1 Answer available

In which cases would you consider early transition to DOAC (within 72 hours) for hospitalized patients with intermediate or high risk PE?

Assume thrombolytics are not indicated. Do you favor early DOAC transition after 24-48 hours of heparin gtt or do you favor LMWH for 10-14 days follow...

2 Answers available

Does your evaluation of a young person with spontaneous upper extremity DVT vary as compared to lower extremity DVT?

Do you do additional workup for venous obstruction or any other different testing/evaluation?

1 Answer available

Do you use direct oral anticoagulants to treat port-a-cath related VTE in patients with an active malignancy?

Do social or economic factors (i.e., relative cost of acquiring LMWH, the patient being injection averse) affect your decision to use DOACs? Do you s...

1 Answer available

How do you treat factor XI deficient patients with surgery or trauma related bleeding?

Is there a factor XI goal that you target? Would you consider FVIIa products instead?

1 Answer available

Is a history of provoked DVT a contraindication to starting testosterone replacement therapy in a middle aged man with symptomatic hypogonadism who is on anti-coagulation?

1 Answer available

How do you manage hemophilia A carriers with no history of bleeding complications but with mildly low factor VIII activity (6-40%)?

1 Answer available

How would you manage anticoagulation in a patient with acute MI or PE with prolonged aPTT due to congenital factor XII deficiency?

1 Answer available

How would you counsel a female to male transgender patient regarding VTE risk with testosterone therapy, who has additional mild-moderate risk factors for thrombosis?

Additional risk factors could be family history of VTE or thrombophilia, such as antithrombin deficiency.

1 Answer available

When do you use clinical decision tools, like HERDOO2 or DASH, to determine duration of anticoagulation in venous thromboembolism?

1 Answer available

How do you manage a patient with no history of miscarriage but who is unable to conceive, who has a positive lupus anticoagulant without diagnosis of antiphospholipid syndrome?

1 Answer available

How would you manage a patient pre-operatively with a prolonged PTT that does not correct on mixing, with lupus anticoagulant testing that is abnormal by LA-PTT only?

Confirmatory tests with DRVVT, hexagonal phase assay, and PNP are all normal. No bleeding history

1 Answer available

Does PT/PTT elevation due to severe vitamin K deficiency protect against thrombosis?

In the setting of requiring anticoagulation for atrial fibrillation and bioprosthetic valve, but also having severe vitamin K deficiency, would you st...

2 Answers available

How would you manage a provoked blood clot for a patient who had been placed on low dose DOAC for history of unprovoked blood clot?

1 Answer available

Are SCDs contraindicated in patients with acute DVTs?

Is it different than early mobility that we always encourage?

3 Answers available

For a patient with May-Thurner syndrome and DVT, would you recommend anticoagulation for 3-6 months or indefinitely?

4 Answers available

Would you recommend indefinite anticoagulation in any scenario of a provoked clot?

E.g. young male, morbid obesity, with BMI >50

1 Answer available

Would you extend the duration of anticoagulation in patients with a provoked DVT, but evidence of residual clot at 3 months?

While follow up ultrasound is not usually recommended in provoked DVT, it often is done either for other reasons or by other physicians. Would this in...

3 Answers available

Do you use FVIII levels to differentiate between DIC and coagulopathy of liver disease?

Common thought is that FVIII may be used for differentiating coagulopathy in liver disease (normal to increased, from reduced clearance of VWF/FVIII) ...

4 Answers available

Is there a role for rituximab in refractory HIT?

1 Answer available

How long do you anticoagulate for cirrhosis patients who have portal vein thrombosis extending to the mesenteric veins?

2 Answers available

How long post operatively do you wait before transitioning from parenteral anticoagulation to oral anticoagulants after pulmonary thromboendarterectomy for CTEPH?

2 Answers available

For an asymptomatic patient discovered during workup for elevated PT/PTT to have mild prothrombin deficiency, would you suggest any preoperative prophylaxis?

Level >60%. No family or surgical h/o of bleeding but heavy postpartum bleeding.

2 Answers available

What are the indications for anticoagulation in splenic infarctions?

What is the work up and what is the duration of anticoagulation if used?

2 Answers available

What is the ideal period to wait until curative surgery for patients with acute pulmonary embolism and solid malignancy?

Specifically, asymptomatic subsegmental PE diagnosed within a month from planned bilateral mastectomy for breast cancer.

1 Answer available

How do you manage me anticoagulation in a patient with May Thurner Syndrome, who does not have history of thrombosis, and becomes pregnant?

1 Answer available

Can you use apixaban or rivaroxaban in case of dabigatran failure?

1 Answer available

Would you give transdermal hormone replacement therapy to a woman with remote history of provoked pulmonary embolism?

Is patch or gel HRT with ASA prophylaxis a reasonable option after counseling? Or do you add a prophylactic DOAC?

1 Answer available

How do you treat a patient with warfarin failure, with therapeutic INR 2-3 at the time of DVT, and no underlying malignancy or hypercoagulable state?

Is lifelong LMWH the anticoagulant of choice? Would DOACs be an option?

2 Answers available

For patients with incidental findings of venous thromboembolism during workup of a treatable malignancy, how do you approach discontinuation after the treatment is complete?

Would you consider low dose indefinite anticoagulation in any scenario? Any difference in approach between hematological malignancy and solid tum...

1 Answer available

In a young female with severe osteoporosis due to congenital estrogen deficiency, can estrogen be prescribed if genetic testing for congenital disorders reveals a heterozygous Factor V Leiden mutation?

No prior thrombosis; no family history of thrombosis. As per endocrine, the only useful therapy for the osteoporosis is estrogen.

1 Answer available

What additional testing besides LAC/APLS, factor V Leiden, prothrombin gene mutation, JAK 2 do you draw for unprovoked cerebral venous sinus thrombosis?

1 Answer available

Would you use PCC for clotting factor repletion in acute life threatening hemorrhage in a patient with elevated INR from coagulopathy of liver disease?

2 Answers available

When should I consider anticoagulation in an unprovoked upper extremity deep venous thrombosis?

For example: In a patient presenting with left arm swelling and found to have a left cephalic vein occlusive thrombus on ultrasound

1 Answer available

Do you repeat images in patients with venous thrombosis to inform decision about duration of anticoagulation?

E.g. pulmonary embolism, portal vein thrombosis, cerebral venous sinus thrombosis

2 Answers available

Is there a role to continue aspirin in patients with myeloproliferative disorders who have never had a thrombotic event that are starting DOAC for stroke prophylaxis with newly diagnosed atrial fibrillation?

2 Answers available

Would you continue warfarin anticoagulation in patients with unprovoked DVT if switching to low-dose DOAC is cost-prohibitive?

2 Answers available

Do you use anticoagulation in cancer patients who develop an unprovoked superficial vein thrombosis?

If so, do you treat for a limited period of time or indefinitely?

1 Answer available

How should elevated PT of unclear etiology and significance be evaluated?

In the absence of concerning bleeding or thrombosis, family history of coagulopathy, current anticoagulant use, or malnutrition

2 Answers available

How do you manage a patient with a nonspecific platelet function disorder and heterozygous protein C deficiency during pregnancy?

Specifically - patient who had mild aggregation defect with ADP which corrected in third trimester of pregnancy. Would it be appropriate or necessary ...

1 Answer available

Do you send an antiphospholipid antibody panel routinely for all patients with an unprovoked thrombus?

2 Answers available

How would you approach the treatment of a patient who, during a hospitalization, was initially diagnosed with TTP and treated with PLEX with good response, but renal biopsy then resulted class IV LN along with changes of thrombotic microangiopathy?

4 Answers available

Would you restart prophylactic anticoagulation in a patient with a history of unprovoked PE who received short term anticoagulation with a prior physician?

E.g. low dose DOAC

1 Answer available

Is there any role in continuing apixaban in a patient with occlusion of the right internal jugular vein with chronic postthrombotic change to prevent a recurrent DVT?

Previous provoking factors resolved (CVC, malignancy, etc)

1 Answer available

How would you manage IVF using ovarian stimulation in a woman with a prior estrogen related thrombotic event?

1 Answer available

For a patient with PE undergoing procedures like port placement in the first month, how do you manage anticoagulation?

What is your preferred agent (DOAC, warfarin, enoxaparin), and is periprocedural bridging necessary?

3 Answers available

In a patient with Type I von Willebrand disease with history of VTE and heavy menses, would tranexamic acid be a treatment option?

Is thrombotic risk too significant? Patient failed OCPs.

3 Answers available

When can abdominal surgery be safely performed for presumptive ovarian cancer in a patient with recent pulmonary emboli?

(Normal oxygenation and echo)

1 Answer available

Do you recommend long term anticoagulation for all patients with first time unprovoked VTE?

1 Answer available

What is the preferred immunosuppressive modality for patients with an acquired factor 8 inhibitor?

1 Answer available

In patients who develop a VTE, what conditions do you consider as persistent, provoking risk factors, and at what point are they controlled enough to stop anticoagulation?

I.e., what constitutes well-controlled cancer, IBD, nephrotic syndrome, etc. What other diseases do you put in this category (obesity, autoimmune dise...

1 Answer available

How would you manage an incidental catheter-related thrombosis in a functioning dialysis catheter?

- Dialysis catheter used for hemodialysis- RIJ thrombus in dialysis catheter was incidentally found- Patient asymptomatic with no prior history of VTE...

2 Answers available

How would you manage someone with antithrombin deficiency who has recurrent VTE on a DOAC?

APLA syndrome, obesity, non compliance ruled out and prefers another oral anticoagulation. Is higher dose of rivaroxaban or apixaban an option?

2 Answers available

Do you always initiate hypercoagulable work up in a patient with recurrent stroke?

If so, what would you consider ordering?

1 Answer available

In a patient with a bleeding disorder, how would one approach anticoagulation during active COVID infection?

Bleeding disorder such as vWD

1 Answer available

How would you approach protein S deficiency found on hypercoagulability work-up in a patient with a post-operative central retinal vein occlusion?

In the setting of no personal or family history and no other risk factors for thrombosis, is systemic anticoagulation warranted if local treatments (e...

4 Answers available

Would you give antithrombin concentrate for surgical VTE prophylaxis in case of congenital AT deficiency?

1 Answer available

How long after starting anticoagulation would you remove an IVC filter in a patient with a DVT presenting with stroke and PFO which is now closed?

1 Answer available

How do you determine duration of anticoagulation for an ovarian vein thrombosis following a provoking event?

1 Answer available

Would you anticoagulate recurrent venous thromboembolism in a patient with Ehlers Danlos syndrome?

How would the approach differ if the patient had a significant bleeding phenotype vs only minor bruising and mucosal bleeding?

1 Answer available

What are the alternatives to anticoagulation in an individual with an atrial thrombus and absolute contraindications to anticoagulation?

1 Answer available

How do you approach heparin management in patients who have suprathetherapeutic Xa levels on minimal heparin?

1 Answer available

Should a pregnant woman who is heterozygous for factor V Leiden who has never had a thrombotic event receive prophylactic anticoagulation?

1 Answer available

Does 4G/5G polymorphism in the plasminogen activator inhibitor (PAI-1) gene increase the risk of thrombosis?

In the absence of a VTE would you consider prophylaxis after a surgical procedure? Often non-hematologists order this testing but we are consulted for...

1 Answer available

Are there any situations you would recommend prophylactic anticoagulation for a patient with Factor V heterozygosity?

FVL heterozygotes are often treated similarly to the general population. Aside from avoiding other VTE risk factors, are there situations where prophy...

1 Answer available

Should we recommend the COVID-19 booster vaccine to patients who had a DVT or any other complications such as hemolytic anemia or thrombocytopenia from prior vaccine doses?

2 Answers available

Is antiplatelet or anticoagulant therapy preferred for the secondary prophylaxis of cryptogenic stroke in a patient with underlying malignancy?

4 Answers available

What is your preferred anticoagulant for acute portal vein thrombosis?

How does cirrhosis and/or underlying thrombophilia affect your decision?

1 Answer available

Would you use new DOAC loading dose or start with maintenance dosing for a stable patient on existing DOAC who needs to switch brand due to insurance/formulary reasons?

Conversion tables suggest starting the new drug with the next dose but do not seem to answer this question (i.e. if switching from rivaroxaban 20 mg d...

1 Answer available

What are your considerations for peri-operative anticoagulation in patients with a mechanical heart valve undergoing a major noncardiac surgery?

Please comment on bridging.

1 Answer available

Does testing for elevated serum homocysteine have any relevance in thrombophilia management?

What should be done with a high level?

1 Answer available

How do you counsel male-to-female transgender patients on the VTE risk of hormonal therapy?

1 Answer available

Are you comfortable using DOACs in obese patients with VTE?

1 Answer available

How do you manage a patient with superficial venous thrombosis with close proximity (<3 cm) to deep veins and an inherited thrombophilia ?

Would you offer indefinite anticoagulation if the event is unprovoked and the patient has low bleeding risk?

1 Answer available

What is your typical workup for a patient with a spontaneous renal infarct?

Please also discuss the type and duration of anticoagulation.

1 Answer available

Are there any circumstances where you consider repeating CT Angiogram Chest after 3-6 months of anticoagulation for pulmonary embolism?

1 Answer available

Is prophylactic anticoagulation indicated in patients with frequent ulcerative colitis flares?

If so, what agent(s) do you prefer?

1 Answer available

Do you utilize D-dimer to inform anticoagulation duration in the treatment of VTE?

Provoked or unprovoked VTE: Do you use D-Dimer (or even repeat imaging to reassess residual clot) in any capacity to guide anticoagulation duration? E...

2 Answers available

How would you manage VTE in a patient with bleeding disorder such as hemophilia?

Have you used anticoagulants other than coumadin? Or is that the only appropriate agent given monitoring is based on PT/INR?

1 Answer available

What is your approach to CLL in patients with atrial fibrillation and/or on anticoagulation?

Do you feel comfortable with BTK inhibitors in these patients? In ELEVATE-RR patients on a/c were excluded, and rate of atrial fibrillation in the ac...

3 Answers available

Do you consider low-dose aspirin for primary thromboprophylaxis in patients with high-risk antiphospholipid antibody profiles?

While low-dose aspirin for primary thrombosis prevention in aPL without APS is not typically recommended outside cardiovascular prevention guidelines ...

1 Answer available

What is the anticoagulation recommendation for a chronic DVT?

2 Answers available

In the rare setting of enoxaparin injection-induced abdominal wall hematoma in patients requiring long-term anticoagulation, what is your timeline for restarting anticoagulation?

Would appreciate expert opinion on when to reimage and when to restart anticoagulation depending on findings.

1 Answer available

Do you recommend anticoagulation for a splenic infarct in patients with myelofibrosis and splenomegaly?

1 Answer available

How soon after a VTE would you feel comfortable with a patient undergoing an elective surgery?

While there are many factors involving:- type (DVT vs PE, unprovoked vs provoked) and severity of venous thromboembolism (VTE) size- duration of antic...

1 Answer available

Under what circumstances would you consider anticoagulation in a young female patient with persistently elevated factor XI activity?

While this is a known risk factor for venous [Meijers et al NEJM 2000] and potentially arterial [Yang et al, Am J Clin Pathol 2006] thrombosis, it is ...

1 Answer available

Should platelet transfusions be considered for anti-platelet agent reversal in patients with major bleeding?

1 Answer available

How do you manage testosterone replacement therapy-induced erythrocytosis?

Do you recommend therapeutic phlebotomy to a certain Hct goal? Any strong evidence for thromboembolic risk related to erythrocytosis or if this is mit...

3 Answers available

How do you advise a patient with VTE on indefinite anticoagulants regarding the Ad26.COV2.S Johnson & Johnson/Janssen COVID vaccine?

1 Answer available

How do you counsel patients on the risk of thromboembolic complications with use of immunotherapy in NSCLC?

Given recent data in Blood (Moik et al, 2021), and the potentially overlapping risks with other clinical factors associated with NSCLC. Will you alte...

3 Answers available

How do you approach evaluation of pulmonary vein thrombosis?

Is there any difference between anticoagulants in this clinical context (e.g. anti-Xa inhibitors vs warfarin vs LMWH)?

1 Answer available

How do you approach the treatment of drug-induced thrombotic microangiopathy?

When do you consider initiating eculizumab?

1 Answer available

Is there a role for anti-fibrinolytic agents in patients with hyperfibrinolytic disseminated intravascular coagulation?

The use of anti-fibrinolytics is typically contraindicated in DIC, but does it have benefit in DIC states characterized by hyperfibrinolysis?

1 Answer available

What is your approach to platelet transfusion in heparin induced thrombocytopenia?

Does having a concurrent consumptive process e.g. DIC change your management?

1 Answer available

In a patient with breakthrough VTE on rivaroxaban, would you switch to apixaban or an agent with a different mechanism of action?

Assuming the patient is a candidate for all anticoagulation options (no mechanical valve, antiphospholipid syndrome, patient-specific contraindication...

1 Answer available

Should patients receive thrombophilia testing in the setting of a provoked VTE secondary to hormonal therapy/OCPs?

While thrombophilia testing is not routinely recommended prior to starting OCPs, how about after the development of a VTE?

2 Answers available

Would you ever consider prophylactic anticoagulation in patients with CKD requiring ESA therapy?

While the CKD population is at high thrombotic and bleeding risk, would you consider anticoagulating a patient prophylactically if they had a history ...

1 Answer available

Is there a role for prophylactic tranexamic acid in patients with hematologic malignancy with chemotherapy-induced thrombocytopenia?

1 Answer available

What is the best way to monitor intraoperative heparin use in a patient with factor XII deficiency?

In a patient with severe factor XII deficiency with a baseline prolonged PTT, what is the best method to monitor their ACT or heparin levels when on c...

1 Answer available

Do you generally reduce DOAC dosing for extended anticoagulation in patients with first unprovoked VTE?

Ref: EINSTEIN-CHOICE and AMPLIFY-EXT Would you approach this differently in patients with inherited thrombophilias?

1 Answer available

How would you manage a patient with PV or ET who is experiencing breakthrough thrombosis?

For example, a patient on cytoreductive therapy and aspirin BID, but suffers an arterial event, or a patient who is already on therapeutic anticoagula...

2 Answers available

How would you manage OCPs in a patient who develops a VTE while on treatment?

In a patient with a medical or personal indication to induce oligomenorrhea/amenorrhea, how would you manage OCP therapy if a patient develops a VTE d...

1 Answer available

Would you place an IVC filter in a patient with an acute PE and an absolute contraindication for anticoagulation, but negative imaging for proximal DVT?

3 Answers available

Are there patients who can forgo anticoagulation with asymptomatic, incidentally discovered subsegmental pulmonary embolism?

If there are a low-risk patients who can be monitored, how would you do so? If unprovoked, would you consider stopping anticoagulation?

2 Answers available

How do you manage VTE in the setting of persistent severe thrombocytopenia?

Is there a preferred strategy of transfusional support versus reduced-dose anticoagulation during the duration of thrombocytopenia?

3 Answers available

Is there any role for direct oral anticoagulants in the treatment of antiphospholipid syndrome?

What if this was "triple-negative" antiphospholipid syndrome?

2 Answers available

How do you evaluate an isolated prolonged aPTT in patients?

Especially in a patient without hemophilia or thrombosis history?

1 Answer available

Do you routinely use risk assessment scores (e.g., the Khorana score) to assess the risk of venous thromboembolism and consideration of prophylactic anticoagulation in ambulatory cancer patients undergoing / about to undergo treatment?

What factors other than the Khorana score influence your decision regarding prophylactic anticoagulation in these patients? If prescribing an agent, w...

0 Answers available

Based on the SELECT-D trial, would you favor rivaroxaban over LMWH for treating cancer-associated VTE in patients with low risk of bleeding?

1 Answer available

Papers discussed in this category

Thrombosis research, 2019-01

Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

The New England journal of medicine, 2018-02-15

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016-04

Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS).

Blood, 2018 Jul 12

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Ann. Intern. Med., 2019 Oct 15

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.

Blood Transfus, 2018 Oct 24

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.

J Thromb Haemost, 2018 May 08

Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH.

AJR Am J Roentgenol,

Overdiagnosis of Pulmonary Embolism by Pulmonary CT Angiography.

J Vasc Interv Radiol, 2020 Sep 09

Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic Disease: Developed in collaboration with the American College of Cardiology, American College of Chest Physicians, American College of Surgeons Committee on Trauma, American Heart Association, Society for Vascular Surgery, and Society for Vascular Medicine.

Blood, 2015 Dec 22

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.

Contraception, 2016 May 03

Progestin-only contraception and thromboembolism: A systematic review.

BMJ, 2008 May 20

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.

Circulation,

Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.

Blood Cancer J, 2018 Feb 09

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Blood, 2017 May 08

How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy.

Blood, 2013-12-05

The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.

Blood Adv,

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Blood,

Five hematologic tests and treatments to question.

Lancet (London, England), 2010-07-03

Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.

J Intensive Care, 2014 Feb 20

Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines.

Thrombosis, 2013

A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis.

Thrombosis journal, 2023 Oct 26

The clinical application of venous ultrasound in diagnosis and follow-up of lower extremity deep vein thrombosis (DVT): a case-based discussion.

PLoS One, 2021 Apr 08

Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study.

The New England journal of medicine, 2016-11-10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-05-31

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-06-14

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Lancet (London, England), 2019-05-04

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Lung cancer (Amsterdam, Netherlands), 2012-12

Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer.

N Engl J Med,

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Blood,

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.

Cancers (Basel), 2019 Dec 25

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

N Engl J Med, 2021 Apr 14

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.

Semin Hematol,

Epidemiology and risk factors for venous thrombosis.

Blood, 2016-07-14

How I treat patients with inherited bleeding disorders who need anticoagulant therapy.

Blood, 2016 Sep 26

New concepts for anticoagulant therapy in persons with hemophilia.

J Thromb Thrombolysis,

Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis.

Circulation, 2012-09-25

Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates.

BMJ, 2021 Jun 09

Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial.

J Am Heart Assoc, 2020 Nov 23

Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.

Am J Hematol,

Protein S abnormalities: a diagnostic nightmare.

Blood advances, 2018-11-27

American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism.

Blood advances, 2018-11-27

American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.

Blood Adv, 2017 Jun 22

Ovarian vein thrombus: to treat or not to treat?

CMAJ,

Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy.

The New England journal of medicine, 2019-01-24

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

N Engl J Med, 2022 Dec 22

Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura.

Int J Lab Hematol, 2021 Oct 05

A single-institution retrospective study of causes of prolonged prothrombin time and activated partial thromboplastin time in the outpatient setting.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2013-10

Refractory heparin induced thrombocytopenia with thrombosis (HITT) treated with therapeutic plasma exchange and rituximab as adjuvant therapy.

Journal of clinical medicine, 2023 Nov 03

Autoimmune Heparin-Induced Thrombocytopenia.

Post reproductive health, 2022 Dec 27

Hormone replacement therapy in women with history of thrombosis or a thrombophilia.

Hepatology, 1996 Jun

Coagulation factor V levels as a prognostic indicator in fulminant hepatic failure.

Hepatology, 1986 Jul-Aug

Multivariate analysis of prognostic factors in fulminant hepatitis B.

Gut, 1992 Jan

Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators.

Hematology. American Society of Hematology. Education Program, 2015

Coagulopathy in liver disease: a balancing act.

J Clin Med, 2020 Mar 10

Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions.

Hematology Am Soc Hematol Educ Program, 2021 Dec 10

Clots in unusual places: lots of stress, limited data, critical decisions.

JAMA Neurol, 2019 Dec 01

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.

J Thromb Haemost, 2021 Jul 14

Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.

Blood, 2020 Mar 19

How I treat obese patients with oral anticoagulants.

Haematologica, 2019 Jan 03

The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.

The New England journal of medicine, 2013-02-21

Apixaban for extended treatment of venous thromboembolism.

The New England journal of medicine, 2017 Mar 18

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Journal of hospital medicine, 2019-01

Things We Do for No Reason: Intermittent Pneumatic Compression for Medical Ward Patients?

The New England journal of medicine, 2019 Feb 18

Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis.

Phlebology, 2020 Mar 02

Risks and contraindications of medical compression treatment - A critical reappraisal. An international consensus statement.

VASA. Zeitschrift fur Gefasskrankheiten, 2001 Jul

Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation.

Journal of vascular surgery, 2000 Nov

Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin.

Blood, 2014 Oct 15

How I treat splanchnic vein thrombosis.

Circulation. Cardiovascular interventions, 2015-10

Safety and Effectiveness of Stent Placement for Iliofemoral Venous Outflow Obstruction: Systematic Review and Meta-Analysis.

Research and practice in thrombosis and haemostasis, 2018 Oct 19

May-Thurner syndrome and thrombosis: A systematic review of antithrombotic use after endovascular stent placement.

Thrombosis and haemostasis, 2019 Oct 28

Incidence of Stent Thrombosis after Endovascular Treatment of Iliofemoral or Caval Veins in Patients with the Postthrombotic Syndrome.

Journal of thrombosis and haemostasis : JTH, 2021 Apr 01

Pediatric May-Thurner Syndrome-Systematic review and individual patient data meta-analysis.

Chest, 2012-02

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

N Engl J Med, 2020 Mar 29

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

Chest, 2021 Oct 08

Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.

Thrombosis journal, 2017 Oct 03

Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis.

The Lancet. Haematology, 2021 Aug 04

Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2023 Jan-Dec

Retrospective Analysis of Direct-Acting Oral Anticoagulants (DOACs) Initiation Timing and Outcomes After Thrombolysis in High- and Intermediate-Risk Pulmonary Embolism.

Journal of thrombosis and haemostasis : JTH, 2019 Sep 13

Transgender patients and the role of the coagulation clinician.

The Journal of clinical endocrinology and metabolism, 2024 Jan 18

Approach to the Patient: Hormonal Therapy in Transgender Adults With Complex Medical Histories.

European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2021 Dec 06

Antithrombotic Management in Adult Kidney Transplantation: A European Survey Study.

Stroke, 2023 Sep 07

Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.

Stroke, 2024 Jan 29

Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association.

Journal of thrombosis and haemostasis : JTH, 2024 Oct 21